Atour Lifestyle Holdings Limited (ATAT)
NASDAQ: ATAT · Real-Time Price · USD
33.46
-0.36 (-1.06%)
At close: Aug 1, 2025, 4:00 PM
33.06
-0.40 (-1.20%)
After-hours: Aug 1, 2025, 7:54 PM EDT
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
The 2 analysts that cover Intra-Cellular Therapies stock have a consensus rating of "Strong Buy" and an average price target of $37.4, which forecasts a 11.78% increase in the stock price over the next year. The lowest target is $36.8 and the highest is $38.
Price Target: $37.40 (+11.78%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 23, 2025.
Analyst Ratings
The average analyst rating for Intra-Cellular Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $37 → $38 | Strong Buy | Maintains | $37 → $38 | +13.57% | May 23, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $36 → $37 | Strong Buy | Maintains | $36 → $37 | +9.09% | Mar 25, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $35 → $37 | Strong Buy | Maintains | $35 → $37 | +9.98% | Mar 14, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $31 → $36 | Strong Buy | Maintains | $31 → $36 | +6.99% | Feb 18, 2025 |
| Citigroup | Citigroup | Strong Buy Reiterates $31 | Strong Buy | Reiterates | $31 | -8.85% | Feb 10, 2025 |
Financial Forecast
Revenue This Year
9.56B
from 7.25B
Increased by 31.86%
Revenue Next Year
11.66B
from 9.56B
Increased by 21.98%
EPS This Year
11.02
from 9.18
Increased by 19.99%
EPS Next Year
13.80
from 11.02
Increased by 25.30%
Financial currency is CNY. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10.0B | 12.7B | 15.2B |
| Avg | 9.6B | 11.7B | 13.9B |
| Low | 8.9B | 10.3B | 12.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 38.4% | 33.2% | 30.3% |
| Avg | 31.9% | 22.0% | 19.4% |
| Low | 23.5% | 8.2% | 10.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 12.77 | 16.34 | 19.97 |
| Avg | 11.02 | 13.80 | 17.58 |
| Low | 3.34 | 4.92 | 14.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 39.1% | 48.3% | 44.7% |
| Avg | 20.0% | 25.3% | 27.3% |
| Low | -63.6% | -55.3% | 3.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.